IAP Q & A on Vaccines and Vaccinology Abhay K Shah, Bakul Jayant Parekh, Srinivas G Kasi, Arun Wadhwa
INDEX
Page numbers followed by f refer to figure and t refer to table.
A
Accidental needle stick injury 159
Acellular pertussis 140
vaccine 138, 139, 140t
Acquired immunodeficiency syndrome 26, 351
Acute lower respiratory infections 197
Acute lung injury, transfusion related 114
Acute respiratory
distress syndrome 190
syndrome coronavirus 345
tract infection 191
Adenovirus
advantages of 364
vaccines 337
Adolescent Vaccination Program 304
Adrenaline 100
Adventitious viruses 364
Adverse Event Following Immunization 50, 72, 75f, 77f, 79, 94, 100, 206, 266, 382
types of 72
Advisory Committee on Immunization Practices 38, 146, 183, 197, 235, 251, 267, 295
Aedes aegypti mosquito 347
Alanine aminotransferase 311
Alcoholism 309
Allergens 3
Allergic disorders 368
Allogenic vaccines 369
Aluminum 328
hydroxide 136
oxide-based nanocarriers 330
phosphate 136
Alzheimer's disease 368, 373
Anaphylactic allergic reaction 200, 287
Anemia, severe 109
Antibody 3
affinity 16
dependent enhancement 357
functions of 8f
mediated organ transplant rejection 109
titers 364
Anti-cyclic citrullinated peptide 372
Anti-D immune globulins 107
Antigen 3
combination 20
dose of 19, 46
polysaccharide vaccine 215
presenting cells 8
Anti-hepatitis vaccine 226
Anti-pertussis toxin 302
Antirabies
immunoglobulin 394
vaccine 394
Antiretroviral therapy 371
Antiviral therapy 291
Anxiety 78
Asplenia 87
Asthma 309
Ataxia-telangiectasia 82
Atherosclerosis 368
Attack rate, secondary 27
Autism, association of 208
Autoimmune
diseases 372
disorders 110
lymphoproliferative disorder 109
Auxiliary nurse midwives 74
B
Bacillus-Calmette-Guérin 42, 119, 124, 339, 388, 389
reaction, classical 121
scar 124
severe complications of 121
vaccination
complications of 121
contraindications of 122
vaccine 119, 123, 373, 393
administration of 120
dosage of 120
role of 373
Bacteria 3
Bacterial infection, prevention of 113
B-cell activation 12
Bell's palsy 252
Bethesda system 240
Bioencapsulation 331
Blepharitis 290
Blindness 290
Blood
dyscrasias 170
transfusion 47
Bloody diarrhea 78
B-lymphocyte 5
deficiency disorders 82
Body mass index 191
Bordetella pertussis 302, 336
Botulism immunoglobulin 110
Bovine rotavirus pentavalent vaccine 164, 165
Breast cancers 369
Breastfeeding 169
Burkitt lymphoma 370
C
Canadian Adverse Events Following Immunization Surveillance System 95
Cancer
cells 369
clinical applications in 369
colorectal 369
Catch-up vaccination 167, 209
Cell-mediated immune response 122
Centers for Disease Control and Prevention 248, 277
Central Drugs Standard Control Organisation 359
Central nervous system 270
Cerebrospinal fluid 183
Cervical cancer 301
problem 241
Cervical intraepithelial neoplasia 240
Chickenpox 2, 228, 304, 312
vaccine 393
Chikungunya virus 350
Chlamydia 324
Chlorpheniramine 100
Cholera 26, 279, 317
vaccines 279, 281, 342, 393
Circumsporozoite protein 335
Cirrhosis 152, 311
Citrobacter freundii 217, 220
Clostridioides 113
Cochlear implants 183
Cold chain 54
elements of 55
equipment, specifications of 63t
management 54
representation of 54f
Colitis 113
Communicable diseases 378
Complement-mediated serum bactericidal activity 264
Complete blood count 114
Complex regional pain syndrome 252
Conjugate vaccine 179, 217, 264
advantage of 177
Convulsions 78
Corneal ulceration 290
Coronavirus disease 2019 5, 124
Cough 266
COVID-19 5, 124, 125
pandemic 365
risk of 355
vaccines 355, 357, 358, 360, 363, 365, 366
accelerated development 356f
efficacy of 366
technology 358t
CoWIN 367
Culex tritaeniorhynchus 270
Cytokines 326
Cytomegalovirus immune globulins 110
Cytotoxic cells 6
D
Dendritic cell 9
role of 10f
vaccines 369
Dengue
vaccine, status of 349
viruses 347349, 357
Deoxyribonucleic acid 151, 153, 239, 291, 324, 326, 345, 347, 369
vaccine 12, 326
basics of 325
Diabetes mellitus 155, 309
Diarrhea 266
severe 78
Diarrheal diseases 162
DiGeorge syndrome 82
Digital data loggers 65, 66f
Digital maximum-minimum thermometers 65, 66f
Diphtheria 30, 112, 302, 306
and tetanus 136
toxoids 102
clinical presentation 113
immunoglobulins 110
pertussis, and tetanus 135, 136, 377, 384, 389
vaccine for 135
pertussis, and vaccine
efficacy of 137
role of adjuvants in 136
tetanus and
acellular pertussis 42
whole-cell pertussis 42
tetanus toxoids 137
and whole-cell pertussis 136, 138, 139t
tetanus, and acellular pertussis 136, 138, 139t
toxoid 140, 146, 265
and acellular pertussis 42
nontoxic variety of 146
Disability-adjusted life years 25
Disodium phosphate anhydrous 294
Dog bite cases 257
Drug Controller General of India 248, 275
Dysgammaglobulinemia 170
E
Ebola virus 346, 346t, 356
disease 345
prevention of 345
infection 346
vaccine 346
Efficacy data
long-term 293t
short-term 293t
Egg allergy 201
Electronic vaccine intelligence network 68
Encephalitis 190, 208, 290
syndrome, acute 270
Endemic disease 26
Endocarditis 174
Enteroviral infections 109
Enzyme-linked immunosorbent assay 180, 280
Epinephrine 100
Epitope 3, 4f
Epizootic disease 26
Epstein-Barr virus infection 109, 370
Equine rabies immunoglobulin 257
Escherichia coli 341
F
Fabricius bursa 5, 45
Fainting 78
Fatty liver disease 311
Filamentous hemagglutinin 136, 140
Fimbrial hemagglutinin 136
Flavivirus 282
Fluorescent antibody 230
Follicular dendritic cells 16, 19
Follicular lymphoma 370
Food and Drug Administration 160, 334, 345
Freeze sensitive vaccines 56
Fungal ligand 5
G
Gastroenteritis 163, 164
Gastrointestinal loss 109
Gastrointestinal tract 171
Geometric mean
antibody titer 246
concentrations 178
titers 231, 274
Germinal center response 15f
Gliomas 369
Global Advisory Committee on Vaccine Safety 95, 252
Glycoconjugate 335
Glycoprotein enzyme-linked immunosorbent assay 230, 231
Graft-versus-host disease 85
Granulomatous disease, chronic 83
Guillain-Barré syndrome 74, 109, 195, 200, 208, 252, 266
H
H1N1
influenza 26, 356
strain 190, 191
H3N2 strain 191
Haemophilus influenzae 7, 31, 144, 178, 180, 213, 385
B
disease 148
infection 144
vaccine 146148, 248
Hand, foot and mouth disease 334
Hansenula polymorpha 153
Healthcare professionals, vaccinations of 311
Hearing loss 290
Heart
and light sensitive vaccines 56
disease
chronic 309
congenital 212
Helicobacter pylori 368
Hemagglutinin 189
Hematopoietic stem cell transplantation 81, 85t, 113, 158, 234
Hemoglobinopathies 183
Hemolytic anemia, autoimmune 109
Hemophagocytic lymphohistiocytosis 109
Hepatic transaminases 114
Hepatitis 150
A 15, 52, 86, 111, 222, 304
infection 222
vaccine 40, 41, 223226, 303
virus 35, 150, 304
autoimmune 311
B 15, 42, 52, 78, 84, 104, 150, 151, 304, 311
candidate vaccine 333
carriers 226
immunoglobulin 109, 158160
infections, chronic 371
problem 150
vaccine 88, 153, 154, 157, 159, 161, 328, 393
virus 150, 151, 151f, 152, 160, 333, 349, 372
C 311, 372
virus 150
D virus 150
E virus 150
infection 223
syndromes, acute 150
vaccine 46
Hepatocellular carcinoma 152
Herpes viruses 323
Herpes zoster 232, 290
history of 312
risk of 229
vaccination 310
Highly active antiretroviral therapy 157
Holoendemic disease 26
Human cytomegalovirus disease 340
Human diploid cell vaccine 256
Human immunodeficiency virus 87, 155, 170, 207, 234, 323, 333
immunization in 88t
infection 113, 121, 287, 315
vaccines, clinical trials for 352, 353
Human leukocyte antigen 373
Human papillomavirus 42, 239, 240, 302, 307, 323, 378
bivalent 243
infection 240, 242, 250
risk factors for 240
symptoms of 239
vaccine 239, 242, 244, 245, 249, 318, 393
contraindications for 252
effects of 250
use of 303
Human rabies immunoglobulin 257
Hyperendemic disease 26
Hyperhemolytic crisis 109
Hyperimmune globulins 107109
Hyperpyrexia 138
Hypertension 309, 318, 368
Hyperventilation 78
Hypogammaglobulinemia 113, 170
Hypotensive-hyporesponsive episodes 138
Hypothyroidism 318
Hypotonic-hyporesponsive episodes 49
I
Immune
deficiencies 110
dysfunction 323
globulins 108
response 17
conjugated vaccines 15
system, function of 3
thrombocytopenia 109
Immunity 3, 10f
active 11
adaptive 4f
cell-mediated 8, 121, 290, 325
cellular 8
herd 30, 30t
humoral 7
innate 4f
Immunization 3
anxiety-related reaction 72
documentation of 52
error-related reaction 72
schedule 146
technical support unit 68
Immunodeficiency
primary 107, 108
severe combined 121, 49, 170
Immunogenicity 208, 217
Immunoglobulin 3, 7, 107, 256
A 234
administration of 115t
G 151, 231, 234, 304
types of 7
use of 108
Immunosuppression 49
In vitro dendritic cell 325
Inactivated influenza vaccine 42, 195
contraindications for 196
efficacy of 196
side effects of 195
Inactivated polio vaccine 42389
fractional dose of 390f
Indian Academy of Pediatrics 38, 76, 146, 169, 195, 200, 235, 258
Indian Council of Medical Research 272
Indian Medical Association 76
Indian Neonatal Rotavirus Live Vaccine 165
Indian Rotavirus Strain Surveillance Network 163
Indirect fluorescent antibody 231
Infections 109
Inflammatory bowel disease 208
Inflammatory disorders 110
Influenza 189, 191, 192, 304, 312, 318, 323
complications of 190
disease burden of 190
management of 192
prevention of 192
severe 191
treatment of 192
type B 194
vaccine 192195, 200, 328, 394
composition of 193
types of 192
viruses 351
Integrated digital thermometers 65, 65f
International Certificate of Vaccination 285
International Health Regulations 285
Intradermal rabies vaccination 259
Intravenous immunoglobulin 230
G 107
doses of 110
use of 108
Invasive bacterial infection surveillance 175
Invasive pneumococcal disease 89, 174, 180
surveillance of 175
J
Japanese encephalitis 39, 270, 270, 304, 317, 389, 390f
control 271
disease burden of 271
prevention of 273
vaccine 270, 274, 276, 317, 394
Program 272
virus 270, 347
Joint pain 266
K
Kawasaki disease 109, 124
Killed oral whole-cell-bivalent vaccine 280, 281
Kolar strain vaccine, salient features of 275
L
Lactobacillus acidophilus 224
Lassa fever virus 345
Leukemia 170
acute lymphatic 236
chronic lymphocytic 109
Leukocyte adhesion deficiency 83
Live-attenuated hepatitis A vaccine 224
Live-attenuated influenza vaccine 198, 199
contraindications of 200
side effects of 199
Live-attenuated vaccines 11, 12
Live-attenuated yellow fever vaccine 276
Liver
cancer, primary 150
disease
alcoholic 311
chronic 226, 309
Low birth weight 159
Lung cancers 369
Lymphocyte antigen 370
Lymphoid tissue
gut-associated 331
nasal-associated 329
Lymphomas 170
Lyssavirus 254
M
Macrophage activation syndrome 109
Major histocompatibility complex 6
Malaria 26, 323, 368
vaccines 334, 335
Malignant cells 3
Mannide monooleate 328
Maternal antibodies 21
Measles 30, 384, 389
containing vaccine 211
postexposure prophylaxis 109
prevention 205
Measles and rubella 390f
vaccination campaigns 211
Measles, mumps, and rubella 42, 52, 208, 230, 304
and varicella 231
and varicella 318
vaccine 213
vaccine 36, 204, 206, 288, 316
contraindications for 207
immunogenicity of 207
Measles, pertussis, and diphtheria 301, 380
Measles, varicella containing vaccine 115t
Medical equipment 100
Medical termination of pregnancy 234
Melanoma 369
Membrane antigen 230
Memory B cells 16
Meningitis 174
belt 303
Meningococcal conjugate vaccine 264, 265, 315
Meningococcal polysaccharide vaccine 15, 265
Meningococcal serogroup B vaccine 268
Meningococcal vaccination 303
Meningococcal vaccine 263, 266, 304, 394
protection for 264
Mental retardation 212
Messenger ribonucleic acid 347
Microarray patch 331
Microneedle technologies 331
Mission Indradhanush 385
Monoclonal antibodies 107, 256
Mucosal vaccination 329
Mucosal vaccine delivery system, concept of 330
Multidose vial policy 68
Multifocal motor neuropathy 109
Multi-organ failure 190
Multiple myloma 108
Multiple sclerosis 233
Multistage vaccine 335
Mumps 30
Muscle 266
Myasthenia gravis 109
Mycobacterial disease 121
Mycobacterium
avium 122
indicus pranii 371
intracellulare 122
marinum 122
tuberculosis 119, 323, 339
vaccae 371
Myocarditis 190
Myositis 190
N
Nasopharyngeal carriage 174, 175
Nasopharyngitis 266
National Immunization Program 38, 124, 149, 153, 161, 168, 184, 263, 301, 306, 384, 386
National Immunization Schedule 387t
National Institute of Allergy and Infectious Diseases 347
National Regulatory Authority 93, 94, 360
National TB Control Program, revised 119
National Vector Borne Disease Control Program 272
Natural infection 152
Natural killer T cells 6
Natural varicella 229
Neisseria meningitides 146, 263, 312, 323
Neonatal alloimmune thrombocytopenia 109
Neonatal rotavirus vaccine 338
Neuraminidase 189
Neuritis 233
Neurologic disease 287
Neurological diseases 368
Neurological disorders 373
Neutralizing antibodies 349
Neutropenia, autoimmune 109
New tuberculosis vaccine 339
New vaccine
development 324
technologies 323
Nipah
glycoprotein 345
viral disease 347
virus 345, 347
disease, prevention of 347
Nonavalent Human papillomavirus vaccine 246
Noncommunicable diseases 368
Non-human adenovirus vectors 364
Noninvasive diseases 174
Nonpneumococcal conjugate vaccine 175
Nonsterile injection 73
Nonsteroidal anti-inflammatory drugs 284, 291
Novel virus 345
vaccine against 345
O
Obesity 368
Ocular palsy 290
Ocular zoster 290
Optimum immunization schedule 37
Oral cholera vaccine 279, 304, 336
Oral polio vaccine 127, 390f
birth dose of 130
characteristics of 126
monovalent 127
types of 126
Oral poliovirus vaccine 42, 126, 156, 169, 378
bivalent 127
Oral rehydration solution 162
Oral typhoid vaccine 216
Oral vaccine 280
Oseltamivir 192
Osteomyelitis 174
Otitis media, acute 180
P
Packing cold box 69
Pain relief 48
Paralytic polio, vaccine-associated 127
Paralytic poliomyelitis, vaccine associated 77
Parasites 3
Paratope 3, 4f
Paratyphoid
A vaccine 215
B vaccine 215
vaccine 215
development of 221, 342
Parvovirus infection, chronic 109
Passive immunity 11
Peramivir 192
Pertussis 30, 302, 307
toxin 136, 140
Phagocytic function disorders 83
Pichia pastoris 349
Plasmodium falciparum 335
Platelet alloimmunization 109
Pneumococcal bacteremia 174
Pneumococcal conjugate vaccine 42, 103, 174, 176, 177, 179, 181, 184, 389, 390, 394
efficacy of 180
Pneumococcal disease 174, 176
Pneumococcal infections 183
Pneumococcal polysaccharide vaccine 15, 176, 184, 394
Pneumococcal serotype 174
Pneumococcal vaccine 182184, 184t, 304
status of newer 187
types of 176
Pneumococcus 174
Pneumonia 174, 180, 290
Polio 30, 126, 384
endgame 129
eradication 127
status of 126
vaccine 40, 126, 316, 394
Polyepitope vaccine, development of 372
Polymerase chain reaction 135, 197, 232, 244
Polysaccharide 335
antigens 18
vaccine 14, 14f, 264, 315
efficacy of 264
Population level effects of vaccination, types of 29
Postexposure prophylaxis 111, 209, 337
Posthematopoietic cell transplantation 108
Postherpetic neuralgia 290
Postlicensure surveillance 94
Post-marketing surveillance, types of 95
Post-transfusion purpura 109
Post-transplant lymphoproliferative disorder 370
Postural orthostatic tachycardia syndrome 251
Postvaccination observation area, requirements of 99
Pregnancy 49
Prehematopoietic cell transplantation 108
Premature newborns, severe sepsis in 109
Programmatic vaccine deliveries 331
Prophylaxis, pre-exposure 111, 258, 337
Protection, serologic correlate of 218
Protein
antigens 18
loss, severe 109
Pseudomonas aeruginosa 217, 218
Purified chick embryo cell vaccine 256
Purified duck embryo vaccine 256
Pyrexia 266
Q
Quadrivalent influenza vaccine 194, 201
efficacy of 197
Quadrivalent meningococcal conjugate vaccine 103, 304
Quadrivalent vaccine 250
Quality-adjusted life years 25
Quillaja saponaria 294
R
Rabies 113, 254, 255, 312
immunoglobulins 110, 256
in dogs 255
transmit 254
vaccine 254, 259, 337
Randomized controlled trial 33, 217
Rapid schedule 154
Recombinant zoster vaccine 86
contraindications for 295
Recurrent infections 109
Re-exposure prophylaxis 256
Renal disease, chronic 156
Renal failure, chronic 155
Renal loss 109
Replacement phenomenon 175
Respiratory infection, acute 196
Respiratory syncytial virus 335
Resuscitation, cardiopulmonary 79
Reverse vaccinology 324
Rhabdomyolysis 190
Rhabdovirus 254
Rheumatoid arthritis 109
Ribonucleic acid 270, 324
vaccines 12, 324
Ringer's lactate 80
Rituximab therapy 84
Rotaviral diarrhea 167
Rotavirus 104, 162164, 167, 338
diarrhea 33
cause of 163
disease 162, 163
gastroenteritis, severe 166
infection 162, 163
strains of 163
vaccination 33
vaccine 42, 78, 162, 164, 165, 167171, 172t, 338, 390, 394
dose of 166, 169
Routine vaccination 276
Rubella 30, 113, 384, 389
control 204, 212
syndrome, congenital 207, 212, 213
vaccine 395
S
Saccharomyces cerevisiae 153
Salmonella
minnesota 294
paratyphi infection 342
typhi 218
Septicemia 174
Seroconversion 28
rate 218t
Serogroups 263
Seropositivity 28
Seroprotection 28
Serum
creatinine 114
glucose 114
Severe acute respiratory syndrome coronavirus 2 26, 124
Severe and serious adverse events following immunization 73
Sexual transmission 152
Sexually active 246
Shake test 67
negative 67f
Shigella vaccine 341
Shingles 290
prevention study 292
vaccine 307
Sickle-cell disease 183
Simple febrile seizures 138
Smallpox 30, 261
vaccine 90
Soft tissue infections 174
Solid organ transplant 81, 234
Spontaneous bacterial peritonitis 307
Squamous intraepithelial lesions 240
Standard immunoglobulins 107
Staphylococcus aureus 324, 342
Streptococcus pneumoniae 89, 177, 178, 323, 324
Strokes 290
Subcutaneous immunoglobulins 107
Subcutaneous immunotherapy 368
Subcutaneous vaccines 44
Sublingual immunotherapy 368
Supplemental immunization activity 128, 210
Swine flu 201
Synthetic peptide vaccines 324
Systemic inflammatory response 190
Systemic lupus erythematosus 109, 233
Systemic vascular inflammatory diseases 109
T
T cell
activation 12
dependent vaccines 15
independent immune response 13
types of 6
T helper cell 5, 122
T lymphocytes 5
Talimogene laherparepvec 369
Temperature monitoring devices 65
Termination of pregnancy 249
Tetanus 112, 302, 307
immunoglobulin 110
dose for 141t
prophylaxis 141
toxoid 140, 146, 301
doses of 142
Tetanus, diphtheria 42, 136, 306
and acellular pertussis 136
vaccine 395
vaccine 395
T-helper cells 6
Therapeutic tuberculosis vaccines 371
Therapeutic vaccines 368, 373
applications of 371
role of 368
scope of 373
status of 372
Thrombocytopenia 233
T-lymphocyte deficiency disorders 82
Toll-like receptors 9, 14
Toxic shock syndrome 109
Traditional vaccine development 356
Trained immunity 5
Transforming growth factor 6, 7
Travelers, vaccination for 272, 314
Treponema pallidum 108
Triplex vaccine 340
Trivalent influenza vaccines 194
Tuberculosis 26, 40, 119, 368
and pertussis 323
Tuberculous skin testing 123
Tumor cells 370
Typhoid
conjugate vaccine 215, 217, 304, 395
fever 215
polysaccharide vaccine 395
vaccine 41, 215, 221
developments in 342
types of 215
VI polysaccharide vaccine 216
U
United States Food and Drug Administration 274
Univalent varicella vaccine 86
Universal Immunization Program 168, 169, 210, 273, 384
vaccines in 388
Upper respiratory tract infection 266
Urine analysis 114
V
Vaccination 3, 284, 299
area, requirements of 99
clinics 98
documentation of 50, 51
procedure 43, 50
recommendations for 85t
records, nonavailability of 52
schedule 19, 37
Vaccine 17, 88
adjuvant-delivery system 331
administration 43, 379
schedule for 235, 390f
site of 389f
adverse effects of 281
adverse event reporting system 96, 251
candidates 358
carrier 70, 70f
concept, vector-based 327
delivery 331
derived poliovirus 128
development 351
documentation of 51
dose, part of 45
doses of 20t
effectiveness 29
efficacy 29, 310t, 348
failure 36
primary 36
secondary 36
hesitancy 379
immunogenicity of 28, 230
impact 30
in fridge, storage of 60, 61
plant-based 331
preventable diseases 306, 314
product-related reaction 72
quality defect-related reaction 72
recipient, documentation of 50
safety 92
network 95
sensitivity of 56t
simultaneous administration of 47
Sputnik V 359
storage of 57
temperature for 57t
subunit 11, 350
temporary storage of 69
types of 11, 264
combination 104
vial monitor 64
interpretation of 64f
Vaccine-preventable disease 301
disease epidemiology of 22
surveillance 33
Vaccinia immune globulins 110
Vaccinology
practice of 377
role in 327
Varicella 52, 228, 304, 312
epidemiology of 228
history of 312
infection 109
Varicella vaccination 233, 236, 237
adverse effects of 233
impact of 232
Varicella vaccine 228230
effect of 232
use of 235
Varicella zoster
immunoglobulin 110
virus 111, 231
Vasculitis 233
Vasovagal syncope 72
Vesicular stomatitis virus 327, 346
Vibrio cholerae 279
infection 317
Viral vector vaccines 337, 350, 351
Virosomes 328
Virus 3
infection 357
Viscerotropic disease 287
Vitamin E 328
Vomiting 78, 266
W
West Nile virus 347
vaccine 348t
Whole-cell inactivated typhoid 215
Whole-cell pertussis vaccine 102, 138
Wiskott-Aldrich syndrome 82
World Health Organization 39, 55, 126, 135, 144, 163, 193, 194, 204, 222, 225, 256, 263, 270, 271, 281
WRSS1 vaccine 341
X
X-linked agammaglobulinemia 82
Y
Yellow fever 90, 282284, 286, 287, 304
clinical features of 283
vaccination 286, 288
vaccine 82, 86, 282, 284, 286, 288, 315, 316, 347, 395
adverse effects of 287
virus, transmission cycles of 282f
Z
Zanamivir 192
Zika virus 347, 357
vaccine 347t
Zostavax 292
Zoster 290
vaccine 290, 292, 297, 307, 311
×
Chapter Notes

Save Clear


IAP Q & A on Vaccines and Vaccinology
IAP Q & A on Vaccines and Vaccinology
Editor-in-Chief Srinivas G Kasi MD DCH Consultant Pediatrician Kasi Clinic Bengaluru, Karnataka, India Executive Editor Bakul Jayant Parekh MD DCH FIAP Senior Pediatrician Director, BPCH Tertiary Care Center Mumbai, Maharashtra, India Editors Arun Wadhwa MD Consultant Pediatrician New Delhi, India Abhay K Shah MD Dped (UNI FIRST) FIAP Senior Pediatrician and Infectious Diseases Consultant Director Dr Abhay K Shah Children Hospital and Pediatric Infectious Diseases Centre, Maninagar Ahmedabad, Gujarat, India Academic Editors Nitin Shah MD DCH Section Head and Consultant Department of Pediatrics PD Hinduja Hospital Mumbai, Maharashtra, India Bhaskar Shenoy MD Head Department of Pediatrics Chief, Division of Pediatric Infectious Disease Manipal Hospitals Bengaluru, Karnataka, India Sanjay Marathe MD DNB Director Colors Intensive Care Hospital and Marathe Children Hospital Nagpur, Maharashtra, India Sanjay Srirampur MD DCH FRCPCH Head Department of Pediatrics Aditya Superspecialty Hospital Hyderabad, Telangana, India Alok Gupta MD (Ped) FIAP Pediatrician and Counselor Pediatric Specialties Clinic Jaipur, Rajasthan, India Foreword Vinod K Paul
Jaypee Brothers Medical Publishers (P) Ltd.
Headquarters
Jaypee Brothers Medical Publishers (P) Ltd
EMCA House, 23/23-B
Ansari Road, Daryaganj
New Delhi 110 002, India
Landline: +91-11-23272143, +91-11-23272703
+91-11-23282021, +91-11-23245672
Corporate Office
Jaypee Brothers Medical Publishers (P) Ltd
4838/24, Ansari Road, Daryaganj
New Delhi 110 002, India
Phone: +91-11-43574357
Fax: +91-11-43574314
Overseas Office
JP Medical Ltd
83 Victoria Street, London
SW1H 0HW (UK)
Phone: +44 20 3170 8910
Fax: +44 (0)20 3008 6180
© 2021, Indian Academy of Pediatrics
The views and opinions expressed in this book are solely those of the original contributor(s)/author(s) and do not necessarily represent those of editor(s) of the book.
All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission in writing of the publishers.
All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.
Medical knowledge and practice change constantly. This book is designed to provide accurate, authoritative information about the subject matter in question. However, readers are advised to check the most current information available on procedures included and check information from the manufacturer of each product to be administered, to verify the recommended dose, formula, method and duration of administration, adverse effects and contraindications. It is the responsibility of the practitioner to take all appropriate safety precautions. Neither the publisher nor the author(s)/editor(s) assume any liability for any injury and/or damage to persons or property arising from or related to use of material in this book.
This book is sold on the understanding that the publisher is not engaged in providing professional medical services. If such advice or services are required, the services of a competent medical professional should be sought.
Every effort has been made where necessary to contact holders of copyright to obtain permission to reproduce copyright material. If any have been inadvertently overlooked, the publisher will be pleased to make the necessary arrangements at the first opportunity. The CD/DVD-ROM (if any) provided in the sealed envelope with this book is complimentary and free of cost. Not meant for sale.
Inquiries for bulk sales may be solicited at: jaypee@jaypeebrothers.com
IAP Q & A on Vaccines and Vaccinology
First Edition: 2021
9789390595082
Printed at:
Contributors
  • Aashay Abhay Shah
    MBBS MD(UNI FIRST) FISPGHAN
    Pediatric Gastroenterologist and Hepatogist at Dr Abhay K Shah Children Hospital and Pediatric Infectious Diseases Centre
    Ahmedabad, Gujarat, India
  • Abhay K Shah
    MD Dped (UNI FIRST) FIAP
    Senior Pediatrician and Infectious Diseases
    Consultant Director
    Dr Abhay K Shah Children Hospital and Pediatric Infectious Diseases Centre,
    Ahmedabad, Gujarat, India
  • Alok Gupta
    MD (Ped) FIAP
    Pediatrician and Counselor
    Pediatric Specialties Clinic
    Jaipur, Rajasthan, India
  • Arun Kumar Manglik
    MD (Ped) DNB (Ped)
    Consultant Pediatrician
    ILS Hospitals
    Kolkata, West Bengal, India
  • Arun Wadhwa
    MD
    Consultant Pediatrician
    New Delhi, India
  • Baldev S Prajapati
    MD DPed FIAP MNAMS
    HOD and Professor
    GCS Medical College
    Hospital and Research Centre,
    Ahmedabad
    Aakanksha Children Hospital and Postgraduate Institution
    Ahmedabad, Gujarat, India
  • Bhaskar Shenoy
    MD
    Head
    Department of Pediatrics
    Chief, Division of Pediatric Infectious Disease
    Manipal Hospitals
    Bengaluru, Karnataka, India
  • Chetan Trivedi
    MD DPed
    Consultant Pediatrician and Neonatologist
    Director
    Neha Children Hospital and Neonatal Center,
    Kankaria Ahmedabad, Gujarat, India
  • Dhanya Dharmapalan
    MD PG Dip in PID (Oxford)
    Consultant in Pediatric Infectious Diseases
    Apollo Hospitals Navi Mumbai and Dr Yewale's Multispecialty Hospital for Children
    Navi Mumbai, Maharashtra, India
  • Harish K Pemde
    MD FIAP
    Director Professor
    Department of Pediatrics
    Kalawati Saran Children's Hospital and Lady Hardinge Medical College
    New Delhi, India
  • Jagdish Chinnappa
    MD
    Consultant Pediatrician
    Manipal Hospital
    Bengaluru, Karnataka, India
  • Jaydeep Choudhury
    DNB(Pediatrics) MNAMS FIAP
    Professor
    Department of Pediatrics
    Institute of Child Health
    Kolkata, West Bengal, India
  • Kamlesh Harish
    MD (Ped)
    Senior Consultant
    Head, Department of Pediatrics
    ESIC Hospital
    Rohini, New Delhi, India
  • M Surendranath
    MD DCH FACI
    HOD
    Department of Pediatrics
    Vijay Marie Hospital
    Hyderabad, Telangana, India
  • Mohit Vohra
    DNB(Paed)
    Director
    Sashakt Child Care Centre,
    Jaipur Consultant CKS Hospital
    Jaipur, Rajasthan, India
  • Nitin Shah
    MD DCH
    Section Head and Consultant
    Department of Pediatrics
    PD Hinduja Hospital
    Mumbai, Maharashtra, India
  • NP Singh
    MBBS MD
    HOD and Senior Consultant at Ayushman Hospital and Health Services
    Dwarka, New Delhi, India
  • P Sivaraman
    MD(Pediatrics)
    Consultant Pediatrician
    Thangam Hospital
    Erode, Tamil Nadu, India
  • Pratima Shah
    MD DPed
    Consulting Pediatrician
    Ankur Institute of Child Health
    Ahmedabad, Gujarat, India
  • Pravin Mehta
    MD DCH
    Consulting Pediatrician
    Hindu Sabha Hospital
    Jack N Jill Nursing Home
    Mumbai, Maharashtra, India
  • Raju C Shah
    MD, DPed FIAP FECPCH(UK)
    Medical Director
    Ankur Institute of Child Health
    Ahmedabad, Gujarat, India
  • Rohit Agrawal
    MD DCH FIAP
    Senior Consultant Pediatrician
    Chandra Jyoti Children Hospital and Rainbow Multispecialty Pediatric Clinic
    Mumbai, India
    Consultant Pediatrician:
    Kohinoor Hospital
    Mumbai, Maharashtra, India
  • Rupesh Masand
    MD
    Senior Professor
    Department of Pediatrics
    National Institute of Medical Science and Research
    Jaipur, Rajasthan, India
  • S Balasubramanium
    MD DCH FIAP FRCPCH
    Medical Director and Head
    Department of Pediatrics and IAP IDCPID Fellowship Coordinator
    Kanchi Kamakoti
    CHILDS Trust Hospital
    Chennai, Tamil Nadu, India
  • S Shivananda
    MD
    Former, Director Professor and Head
    Department of Pediatrics
    Indira Gandhi Institute of Child Health
    Former Professor and HOD,
    Bangalore Medical College and Medical Superintendent
    Vanivilas Hospital for Women and Children, Bengaluru
    Presently, Academic Head Department of Pediatrics Fortis Hospital
    Bengaluru, Karnataka, India
  • Sanjay Marathe
    MD DNB
    Director
    Colors Intensive Care Hospital and Marathe Children Hospital
    Nagpur, Maharashtra, India
  • Sanjay Srirampur
    MD DCH FRCPCH
    Head
    Department of Pediatrics
    Aditya Superspecialty Hospital
    Hyderabad, Telangana, India
  • Silky Mittal
    MD
    Ex fellow
    IAP Pediatric Infectious Diseases
    Kanchi Kamakoti Childs Trust Hospital
    Chennai, Tamil Nadu, India
    Assistant Professor
    Sri Aurobindo Institute of Medical Sciences
    Indore, Madhya Pradesh, India
  • Srinivas G Kasi
    MD DCH
    Consultant Pediatrician
    Kasi Clinic
    Bengaluru, Karnataka, India
  • Suhas V Prabhu
    MD DCH MNAMS
    Consultant Pediatrician
    PD Hinduja Hospital
    Mumbai, Maharashtra, India
  • Sumitha Nayak
    MD DNB FIAP Adv Cert in Vaccinology (IVI) PGDMLS PGDGC
    Consultant Pediatrician
    The Children's Clinic
    Bengaluru, Karnataka, India
  • Tanu Singhal
    MD MSc
    Consultant Pediatrics and Infectious Diseases
    Department of Pediatrics
    Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute
    Mumbai, Maharashtra, India
  • Vijay Kumar Guduru
    MD (Peds) ACME
    Professor of Pediatrics
    MGM Hospital/Kakatiya Medical College
    Warangal, Telangana, India
  • Vijay Yewale
    MD DCH
    Head
    Institute of Child Health
    Apollo Hospitals, Navi Mumbai
    Director
    Dr Yewale Multispecialty
    Hospital for Children
    Navi Mumbai, Maharashtra, India
Foreword
I am happy to note that the Indian Academy of Pediatrics is publishing a book on common queries on immunizations encountered by healthcare professionals involved in childcare.
In India, children below five years account for 10% of the total population, a group which contributes a significant burden to the morbidity and under five mortality rate associated with infectious diseases. The Universal immunization program (UIP) of GOI has contributed significantly to the reduction of Vaccine preventable diseases (VPDs). The Intensified Mission Indradhanush launched on 25 December 2014 has further contributes to the increased coverage of the UIP vaccines. In recent years, many new vaccines have been introduced in the UIP.
Vaccinology is constantly evolving field and it is essential for healthcare professionals to remain updates. I am happy to note that this book discusses the commonly used vaccines and the basics of vaccinology. In addition, newer vaccine technologies, future vaccines and therapeutic vaccines are also discussed. Ethical issues of vaccinations and vaccine hesitancy, which have assumed significance, are also covered.
I am sure that this book will go a long way in a educating those involved in childcare, in the essentials of vaccinology and contribute to the enhancement of quality childcare in India.
Vinod K Paul
Preface
Vaccination is widely considered as one of the greatest medical achievements of the 20th century. Childhood diseases that were frequently seen less than a generation ago, are now infrequently seen, largely due to vaccines and vaccination programs. In 1979, Smallpox was declared to have been eradicated. The scourge of polio, which devastated the world, leaving many crippled, is largely controlled. In most of the developed world, the incidence of tetanus, diphtheria, Hib and pneumococcal infections have been drastically reduced. In the words of Dr Stanley Plotkin “next to clean water, no single intervention has had so profound an effect on reducing mortality from childhood diseases as has the widespread introduction of vaccines”.
It should be noted that the benefits of newer vaccines were experienced by the developed countries before it could percolate to the lesser developed countries (LDC), where the need was more acute. Till the recent past, it took at least a decade before the newer vaccines were introduced in the LDC. The advent of international health financing agencies like the GAVI and the Bill and Melinda Gates foundation, has hastened the introduction of newer vaccines in the LDC. The rotavirus vaccines and the Pneumococcal Conjugate vaccines (PCV) have been introduced in the LDC almost in parallel with their introduction in the developed countries.
In India, the Expanded Program of Immunizations (EPI) was introduced in 1978 with BCG, OPV, DPT and the whole cell Typhoid vaccines. In 1985, the Universal Immunization program was launched with BCG, OPV, DPT and measles vaccine. TAB vaccine was dropped. For almost two decades no new vaccines were introduced. This was followed by Hepatitis B vaccines, Hib as part of the pentavalent vaccine, IPV and the MR vaccines. Rotavirus vaccines and the PCVs have been introduced sub-nationally.
In the private sector, the introduction of new vaccines has been more rapid and the uptake is also rapid. To date, almost every childhood vaccine in use in the developed countries, are available in the private sector in India.
Every vaccine has its own characteristics, indications, contraindications, interactions with other vaccines, storage conditions and special use recommendations.
Moreover, knowledge about general aspects of vaccinology are also important in day-to-day practice.
Vaccine hesitancy is rearing its ugly head and needs to be tackled in a gentle but effective manner.
Textbooks of vaccines are too lengthy and unsuitable for quick references. For the practitioner, having all this information in a concise and easily readable form is a necessity.
With this objective, the Indian Academy of Pediatrics (IAP), has published this comprehensive book in a question and answer format, brief enough to be easily readable and with adequate information to answer all the questions.
Each chapter has been authored by experts in the field of vaccinology drawn from all over the country. These experts have delved into the literature about vaccines and formulated these all-inclusive chapters.
It is our fervent hope that this book satisfies the needs of postgraduate students, practitioners and everyone involved in the care of children.
Jai IAP, Jai Hind
Editorial Board
Message
Dear Fellow IAPians,
Greetings from Indian Academy of Pediatrics.
It gives me a great honor to write a message from the desk of National President of IAP. I remember discussing the possibility to come up with the first ever IAP's book on various FAQs regarding vaccines with the national convenor of ACVIP committee - Dr Srinivas G Kasi in the beginning of this year. I am very happy to know that Dr Srinivas G Kasi and his team has left no stone unturned in making this dream of mine come true.
We all have heard about the maxim - “Prevention is better than cure”. The best example of this maxim that I can think of is for vaccines and immunization. In fact, I believe that immunization is the most cost effective invention of the millennium. We know that immunization and vaccine development is a highly dynamic science. Louis Pasteur invented vaccine to prevent Smallpox and since then many more vaccines are being added every year.
Initially there were just a few vaccines. Now, there are a number of vaccines available, some are included in the UIP by the Government, while some vaccines, not included in the UIP, are strongly recommended by IAP. These differences in recommendations often lead to queries in the minds of parents and the Healthcare workers (HCWs). This book to aims to empower those HCWs, responsible for childcare, to gain the knowledge to answer all queries regarding vaccines and vaccinations.
Vaccine hesitancy is rearing it's ugly head all over the world and India is no exception. I am happy to note a full chapter, discussing this issue.
Keeping the above points in mind, the dynamic team of ACVIP led by Dr S G Kasi et al., have come up with answers to many questions in the minds of practising pediatricians and many other healthcare workers. I am certain that this ready reckoner will find its place in many of our libraries - physical as well as digital. I am certain that this ready reckoner will continue to evolve and help many of us for many generations to come. I believe that this is a must have book in every Pediatrician's clinic.
I congratulate the team of editors and contributors who have burnt the midnight oil to bring this masterpiece to our table and helping me in achieving one more milestone and dream this year. I, as a national president and the Chairman of ACVIP committee, compliment the team for the excellent work in spite of the difficult time due to Covid-19 Pandemic. Kudos and three cheers!
Bakul Jayant Parekh
President, 2020
Indian Academy of Pediatrics
Message
I am delighted to know that the IAP is coming out with a book answering the common and uncommon questions in Vaccinology, with Dr Srinivas G Kasi as the Chief Editor. I am sure that with the expertise of all the contributors, this multiauthor, multifaceted book will prove to be a treasure house of knowledge for both practicing pediatricians and postgraduate students. I wish all the success for this venture.
Piyush Gupta
President, 2021
Indian Academy of Pediatrics
Message
Dear Academician Friends,
It is quite heartening to note our Academy is launching a book on FAQs in Vaccinology. As the title implies, this is certainly a comprehensive reference source for all the vaccines which are in vogue.
Our fraternity being the stake holders of wellness of children of our country, are always passionate to provide the most optimal immunization care to our wards. Keeping updated and leaning back to the basics is mandatory to choose and deliver the vaccines and counsel the care takers appropriately.
I am sure Dr Srinivas G Kasi and Team have delivered the goods on immunization front in a consolidated FAQ pace through this book. The vaccinology experts have gone an extra mile to ensure all anticipated queries on immunization domain have been addressed in this unique scientific venture.
I wish this resourceful book on FAQs on Immunization will be a rich addition to the desktop of our fellow academicians in the pediatric segment. Alongside, I congratulate the Editorial and Central IAP Team for this novel initiative.
Remesh Kumar R
President Elect, 2022
Indian Academy of Pediatrics
Acknowledgments
The Editorial Board acknowledges the efforts of Shri Jitendar P Vij (Group Chairman), Mr Ankit Vij (Managing Director), Ms Chetna Malhotra Vohra (Associate Director–Content and Strategy), Ms Pooja Bhandari (Production Head), and Dr Rajul Jain (Development Editor) of M/s Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, India, for their commendable efforts in ensuring the publication of this book in time, in spite of the difficulties caused by the Covid-19 pandemic, the national lockdown and suspension of all activities for a period of time.
The Editorial Board is ever thankful to Dr Bakul Jayant Parekh, President IAP 2020, for initiation of this project and his continued guidance at all times.
The Editorial Board acknowledges the support and encouragement of Dr Piyush Gupta President, IAP 2021 and Dr G V Basavaraja HSG 2020–22.
The Editorial Board acknowledges the consent of the IAP Advisory Committee on Vaccines and Immunization Practices (ACVIP), for utilizing some excerpts from the “IAP Guidebook on Immunization, 2018–19.”